Part B YES NO N/A COMMENTS Is the best practice/intervention a meta-analysis or primary research?
HCV diagnosis and management practice guidelines; Summary of recommendations contained within the guidelines are based on the best available evidence (high quality trials, studies, meta-analysis, systemic reviews or expert opinions) and tailored to HCV patients treated in Saudi Arabia.
The best practice/intervention has utilized an evidence-based approach to assess: Efficacy
Recommendations graded on the basis of evidence (RCTs, meta-analysis, expert
Criteria Grid Best Practices and Interventions for the Diagnosis and Treatment of Hepatitis C opinions etc) Effectiveness
Recommendations graded on the basis of evidence (RCTs, meta-analysis, expert opinions etc) The best practice/intervention has been evaluated in more than one patient setting to assess: Efficacy
Grading of recommendations does not include references Effectiveness
Grading of recommendations does not include references
YES NO N/A COMMENTS The best practice/intervention has been operationalized at a multi-country level:
The SASLT guidelines are specific to chronic hepatitis C infections in Saudi Arabia.
There is evidence of capacity building to engage individuals to accept treatment/diagnosis
There is evidence of outreach models and case studies to improve access and availability
Do the methodology/results described allow the reviewer(s) to assess the generalizability of the results?
The guidelines were approved and endorsed by SASLT through critically examining a broad search of published literature, content expert input/opinion and a final review by the board of directors. The guidelines need to be updated once additional information regarding direct-acting antiviral therapy is available for the large population of patients with few therapeutic options.
The Saudi Association for the Study of Liver diseases and Transplantation (SASLT) formed a task force to evaluate the current epidemiology, trends in, and management of the Hepatitis C Virus (HCV) infection in Saudi Arabia. A majority of the members of the committee were hepatologists.
The first step was a broad literature search of published literature on every aspect of the epidemiology, natural history, risk factors, diagnosis and management of HCV. All available literature on the topic was examined critically, and the available evidence was then classified according to its importance.The recommendations contained in it, have been discussed in detail and agreed upon by members of the SASLT task force. The document was also reviewed by a content expert from another country and valuable additional input was incorporated. Subsequently, and after review by the board of directors, the guidelines were approved and endorsed by SASLT.
All recommendations in these guidelines are based on the best available evidence, and tailored to patients treated in Saudi Arabia. They are graded on the basis of evidence.
The purpose of these guidelines is to improve HCV patient care in the Kingdom, and to promote and improve the multidisciplinary care required in the treatment of these patients. They are intended for use by physicians, and offer recommended approaches to the diagnosis, treatment and prevention of HCV. The current document provides a summary list of the recommendations contained within the guidelines.
GRADING OF RECOMMENDATIONS Grade A
Recommendation based on at least one high quality randomized controlled trial or at least one high quality meta-analysis of methodologically sound randomized controlled trials.
Grade B
Recommendation based on high quality case-control or cohort studies or a high quality systematic review.
Grade C
Recommendation based on non-analytic studies (case reports or case series).
Grade D
Recommendation based on expert opinion only.
GOALS OF THESE GUIDELINES
These are as follows: 1. To provide a concise, evidence-based review of the diagnosis and management of chronic HCV infection in Saudi Arabia. The Saudi Journal of Gastroenterology 2. To help initiate plans to prevent HCV infection in the population. 3. To achieve early and accurate diagnosis of patients with HCV infection. 4. To provide an evidence-based approach for the management of HCV-infected patients. 5. To facilitate appropriate and timely referrals between primary, secondary, and tertiary care providers. 6. To identify gaps in the knowledge and understanding of the incidence of HCV in Saudi Arabia that require further research. • Who were notified that they had received blood from a donor who later tested positive for HCV infection • Who received a transfusion of blood or blood products before July 1992 • Who underwent an organ transplant before July 1992 d. Children born to HCV-infected mothers. e. Health care, emergency medical and public safety workers after a needle stick injury or mucosal exposure to HCV-positive blood. f. Sexual partners of HCV-infected persons. 2. Individuals found to have HCV infection should be counseled regarding prevention of the spread of the virus to others. They should be informed that transmission occurs through contact with their blood, and they should therefore be informed about how to take precautions against the possibility of such exposure (Grade B). The Saudi Journal of Gastroenterology of fibrosis, and the presence or absence of cirrhosis. It is not mandatory, and should only be considered in patients who are hesitant about HCV treatment, in order to make decisions regarding urgency of treatment. Standard histological scoring systems by a suitably experienced pathologist should be used to encourage uniformity of histological reports. In addition, the risks and benefits of liver biopsies should first be carefully explained to the patient (Grade B).
EPIDEMIOLOGY

NATURAL HISTORY
TREATMENT OF CHRONIC HCV PATIENTS
Indications and contraindications of antiviral therapy Recommendations
Eradication of HCV infection is the primary purpose of antiviral therapy (Grade A). 2. Patients with chronic HCV infection who have had
no prior therapy and have compensated liver disease should be evaluated and considered for anti-HCV therapy (Grade B).
Treatment regimen and antiviral side effects Recommendations
In chronic HCV non-genotype 1 infected patients with normal renal function, combination therapy with pegylated IFN-α (peg-IFN) and ribavirin (RBV) is considered the standard of care (Grade A). 2. After initiating combination antiviral therapy, patients
should be seen at monthly intervals in the first three months, and then every two to three months until the end of treatment. Patients who have completed the treatment regimen should be seen six months after the end of treatment. Individualized close follow up should be planned, based on the severity of any adverse events (Grade D).
Adverse events associated with pegylated interferon and ribavirin Recommendations
1. The peg-IFN-α and RBV should be temporarily interrupted if the absolute neutrophil count (ANC) falls below 500/mm 3 , or hemoglobin falls below 8.5 g/dl respectively (Grade A). The combination of peg-IFN-α and RBV should be stopped if severe hepatitis flare or severe sepsis occur (Grade C). 2. The use growth factors is associated with an increased cost of therapy and a lack of sufficient evidence towards improvement of sustained virologic response (SVR) (Grade B). When deciding to use recombinant erythropoietin (EPO) and G-CSF, an 80% or more of RBV and peg-IFN-α dose should be maintained during the course of therapy so that the benefit of adherence can be achieved (Grade D).
Peg-IFN-α-induced neutropenia does not correlate with increased frequency of infection episodes (Grade C). The use of granulocyte colony-stimulating factor (G-CSF) does not reduce the rate of infections (Grade C).
Improving treatment success rates Recommendations
1. In order to optimize SVR rates, complete adherence to both peg-IFN-α and RBV regimens should be emphasized (Grade B). 2. Pre-treatment weight reduction in obese individuals and good control of diabetes mellitus may increase the chance of SVR (Grade B). 
TREATMENT OF CHRONIC HCV NAÏVE PATIENTS Genotypes 1 and 4 HCV infection Recommendations
Genotypes 2 and 3 HCV infection Recommendations
1. Treatment with peginterferon plus ribavirin should be planned for 24 weeks; the dose for peg-IFN-α2a (Pegasys  ) is 180 µg subcutaneously per week, and for peg-IFN-α2b (PegIntron  ) is 1.5 µg/kg subcutaneously per week, together with 800 mg RBV (Grade A). 2. Adequate RBV doses at 15 mg/kg should be administrated to patients with genotypes 2 and 3 who have baseline factors that predict low responsiveness to peg-IFN, such as obesity and cirrhosis (Grade D).
Genotype 5 and 6 HCV infection Recommendations
1. Treatment with peg-IFN plus ribavirin should be planned for 48 weeks; the dose for peg-IFN-α2a (Pegasys  ) is 180 µg subcutaneously per week, and for peg-IFN-α2b (PegIntron  ) is 1.5 µg/kg subcutaneously per week, together with a weight-based dosage of RBV (Grade C).
Direct-acting antivirals in treatment naïve patients Recommendations
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The Saudi Journal of Gastroenterology Individualized treatment duration according to on-treatment virologic response Recommendations 1. A highly sensitive quantitative HCV RNA PCR with a lower limit of detection of 50 IU/ml or less should be used when treating HCV infection (Grade A). 2. Before initiating antiviral therapy, patients must have genotyping performed. Knowledge of the HCV genotype will determine the dose of ribavirin and treatment duration (Grade A). 3. Antiviral therapy must be discontinued if patients fail to achieve more than 2 log reduction in HCV RNA at week 12 of treatment (Null response)(Grade A).
Patients who achieve more than 2 Log reduction in HCV RNA at week 12 but remain detectable (≥50 IU/ ml) at week 24 should discontinue treatment (partial response) (Grade A). 4. Shortening the duration of antiviral therapy in patients who achieve rapid virologic response (RVR) should also be attempted in patients who lack pretreatment negative predictors (Grade B). 5. Extension of antiviral therapy to 72 weeks should be considered in HCV genotype 1 and 4 patients if delayed virological response is obtained (Grade A). Similarly, patients with genotypes 2 and 3 who have no RVR with pre-treatment negative predictors, may be considered for extention of the treatment to 48 weeks (Grade C).
RE-TREATMENT OF EXPERIENCED CHRONIC HCV PATIENTS
Recommendations
1. HCV patients with non-genotype 1 infection experiencing prior non-response or relapse after nonpeg-IFN therapy with or without RBV, or previously treated with peg-IFN monotherapy, may be considered for a second course of therapy with peg-IFN plus RBV (Grade B). 2. HCV patients with non-genotype 1 infection who had previously shown a null or partial response pattern, where an adequate dose of peg-IFN and RBV had been administered during the first course of antiviral therapy, should not be subjected to another course of combination therapy using same or different peg-IFNs (Grade B). These patients should be followed up for progression of liver disease and could wait for new, more effective protease inhibitors (Grade C). 3. Non-responders or relapser patients with genotype 1 HCV infection after treatment with either peg-IFN or non-peg-IFN should be considered for re-treatment with a triple therapy regimen, using direct acting antiviral agents (Grade A).
Role of maintenance antiviral therapy in nonresponders Recommendations 
CONCLUSIONS
SASLT Guidelines for HCV provided a concise, updated, evidence-based review of the diagnosis and management of chronic hepatitis C virus infection in Saudi Arabia. This may help to initiate plans to prevent HCV infection in the population, to bring about early and accurate diagnosis of patients with HCV infection, to facilitate appropriate and timely referrals between primary, secondary, and tertiary care providers and to identify gaps in the knowledge and understanding of the incidence of HCV in Saudi Arabia that require further research. As noted above there is a large population of patients with few therapeutic options, and direct-acting antiviral therapy has become the focus of investigations and once additional information is available, this guideline needs to be updated. The Saudi Journal of Gastroenterology
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